Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibition for Reversal of Squamous Dysplasia in High Risk Smokers
NCT03347838Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2019
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in bronchial dysplasia, sponsored by University of Colorado Denver. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
bronchial dysplasia
Beyond the preview
Go deeper on NCT03347838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347838.